Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 11, 2012, Pages 1362-1367

  Ko, Soon Young ^a   Choe, Won Hyeok ^a   Kwon, So Young ^a   Kim, Jeong Han ^a   Seo, Jung Woong ^a   Kim, Kyun Hwan ^a   Lee, Chang Hong ^a  

^a Konkuk University School of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Entecavir; Partial virologic response

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PARTIAL VIROLOGIC RESPONSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS LOAD;

ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84867568980     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.719927     Document Type: Article

References (18)

1. EASL. Clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42.
2. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis.B. Lancet 2003;362:2089-94.
3. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chemother 1997;41:1444-8. (Pubitemid 27289665)
4. Jardi R, Rodriguez-Frias F, Schaper M, Ruiz G, Elefsiniotis I, Esteban R, et al. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients. J Viral Hepat 2007;14:835-40. (Pubitemid 350211405)
5. Chang TT, Lai CL, Kew Yoon S, Lee SS, Coelho HS, Carriho FJ, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010;51:422-30.
6. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14.
7. Chae HB, Kim JH, Kim JK, Yim HJ. Current status of liver diseases in Korea: hepatitis B Korean. J Hepatol 2009;15: S13-24.
8. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5: 890-7. (Pubitemid 47127032)
9. Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Multimer D, Deterding K, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011;54:443-51.
10. Lampertico P. Partial virological response to nucleos(t)ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009;50:644-7.
11. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004;40:837-44. (Pubitemid 38507366)
12. Yang H, Qi X, Sabogal A, Miller M, Xiong S, Delaney WEt. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther 2005;10:625-33. (Pubitemid 41224954)
13. Hadziyannis SJ. Milestones and perspectives in viral hepatitis B Liver. Int 2011;31:129-34.
14. Zoulim F, Perrillo R. Hepatitis B: reflections on the current approach to antiviral therapy. J Hepatol 2008;48:S2-19.
15. Lai CL, Gane E, Liaw YF, Hsu CW, Tongsawat S, Wang Y, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357: 2576-88. (Pubitemid 350294224)
16. Lee M, Keeffe EB. Study of adherence comes to the treatment of chronic hepatitis B. J Hepatol 2011;54:6-8.
17. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12-18.
18. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004;48:3498-507. (Pubitemid 39129351)